Safety and Trough Concentrations of Nevirapine Prophylaxis Given Daily, Twice Weekly, or Weekly in Breast-Feeding Infants From Birth to 6 Months
Avinash K. Shetty(Wake Forest University), Mary T. Bassett(Physicians for Human Rights), David Katzenstein(Stanford University), Anthony Mwatha(Fred Hutch Cancer Center), Lynda Emel(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Samuel Adeniyi Jones(National Institutes of Health), Kathy George(Family Health International 360), Jennifer Wells(University of Zimbabwe), Susan H. Eshleman(Johns Hopkins University), Salim S. Abdool Karim(Centre for the AIDS Programme of Research in South Africa), Lynne Mofenson(Elizabeth Glaser Pediatric AIDS Foundation), Thomas R. Fleming(University of Washington), Hoosen Coovadia(University of KwaZulu-Natal), Yvonne Maldonado(Palo Alto University), Mark M. Mirochnick, Charles C. Maponga(University of Zimbabwe)
JAIDS Journal of Acquired Immune Deficiency Syndromes
November 24, 2003
Cited by 64
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
|Circulation|2004|1.2k